Kornimate/medical-research-clean huggingface dataset:
exercise in breast cancer survivors

Conditions: Breast Cancer

Summary: the purpose of this study is to compare the effects of aerobic exercise to usual care in women treated with chemotherapy and radiation therapy for non-metastatic breast cancer

in this study, we will compare the effects of exercise between women previously treated with breast cancer to women with no history of any cancers. therefore, in addition to a randomized controlled trial in women with previous breast cancer (i.e., an exerciser group and a control group), we also include a reference group comprising age-matched women with no history of any cancer diagnosis. women in the reference group will undergo a similar exercise intervention and the exercise group. this study recruits through invitation only. the primary endpoint in this study is the change in cardiorespiratory fitness, measured as vo2peak. secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, endpoints derived from the cardiopulmonary exercise test and lung function assessments, cellular muscle endpoints derived from muscle biopsies obtained from m. vastus lateralis, also patient-reported outcomes.

Eligibility criteria:
inclusion criteria: * eligible bcs must be listed in the norwegian cancer registry * female * adult-onset breast cancer diagnosis, diagnosed between 2008 and 2012 * 60 years or younger at the time of diagnosis * received anthracycline-based chemotherapy as a part of their treatment history * signed informed consent and medical doctors approveal of participation prior to inclusion exclusion criteria: * received herceptin * diagnosed with stage iv breast cancer * relapse since diagnosis * a history, or current presence, of another diagnosis of invasive cancer of any kind * selfreported severe fatigue * present with any uncontrolled- or recent cardiovascular disease, has undergone heart surgery or uses a pacemaker * currently exercising more than 90 minutes per week
nurses' negative words and postoperative pain management

Conditions: Postoperative Pain

Summary: psychological implications expressed pivotal effects on daily activities. postoperative pain management is always encountered varying influence from the ambience of surgical wards, especially the nurses. we hypothesized that nurses' negative or positive words would produce unexpected role in pain management, which might be a strong factor resulting in the failure of postoperative analgesia.


Eligibility criteria:
inclusion criteria: * chinese * abdominal surgery * \> 18yr \< 65yr * female * administration of postoperative analgesia * patient-controlled analgesia exclusion criteria: * with cardiac or/and pulmonary diseases * allergy to opioids * \> 20% alteration in vital signs * unwilling to finish the follow-up process * respiratory depression * \> = 65yr = \< 18yr * non-chinese

Keywords: psychological tests pain, postoperative nurses
littlears auditory questionnaire: validation study in ci children

Conditions: Hearing Loss

Summary: the littlears auditory questionnaire is designed to assess the development of the auditory behavior in children during the first two (hearing) years. the questionnaire has been validated on children with normal hearing whose native language is german. a comparison was made between north american english speaking children with normal hearing and found that it was consistent with the german data. this study is to validate the questionnaire in children with cochlear implants.


Eligibility criteria:
inclusion criteria: general: * less than or 24 months of age prior to implantation * cochlear implant candidate deemed by the clinic * to be implanted with a med-el cochlear implant pulsarci100 or sonatati100 * english as the primary language at home * realistic expectations of guardians * willing and available to comply with all scheduled procedures as defined in the protocol medical: * good general health status, as judged by primary investigator * no contraindications for surgery, in general, or cochlear implant surgery in particular exclusion criteria: general: * prior experience with any cochlear implant system * older than 24 months at time of implantation medical: * severed or non-functional auditory nerve in the ear(s) to be implanted * cognitive and/or neurological dysfunction

Keywords: sensorineural hearing loss cochlear implant
examining caffeine as a treatment for antidepressant-induced arousal dysfunction in women

Conditions: Female Sexual Arousal Disorder

Summary: antidepressants have negative effects on genital arousal function that hinder quality of life and jeopardize medication adherence. moderate sympathetic nervous system (sns) activation through exercise has shown promising results for improving antidepressant-induced genital arousal dysfunction. it is feasible that caffeine - an sns stimulant - could improve antidepressant-induced genital arousal difficulties if ingested prior to sex. the goal of the present pilot study is to examine whether the acute administration of 300mg of caffeine increases genital arousal in women experiencing antidepressant-induced genital arousal difficulties. women will attend two counterbalanced sessions in which they ingest either 300mg caffeine or placebo. fifteen minutes after ingestion, they will view an erotic film while their heart rate and genital sexual arousal are measured. caffeine could serve as a low-cost, widely accessible intervention with minimal side effects if efficacy is shown.


Eligibility criteria:
inclusion criteria: * between the of ages 18-55 * fluent in english * experience antidepressant-induced arousal difficulties * experience regular menstrual periods (i.e., not perimenopausal or menopausal) exclusion criteria: * a history or current diagnosis of panic attacks or panic disorder * a history or current diagnosis of sexually transmitted disease(s) * a history of major pelvic surgery that caused nerve damage * currently taking beta blockers, antipsychotics, anti-anxiolytics, hormonal contraceptives (unless the participant has been taking it for over 3 months), or any other medical treatment to enhance sexual response * other medical conditions or procedures that would preclude the participant's participation in the study (e.g., urinary tract infection, neurological impairment due to diabetes or stroke, or spinal cord damage) * a history of childhood sexual abuse (csa) that occurred prior to age 16

Keywords: female sexual dysfunction female sexual arousal disorder caffeine
decompression of odontogenic cysts

Conditions: Odontogenic Cysts; Keratocysts of the Jaw; Cysts Dental; Pathology

Summary: the aim of this case-control study is to evaluate the effects of decompression of cystic jaw lesions by means of comparing pre- and post-decompression histologic findings. the main question it aims to answer is: does decompression of cystic jaw lesions alter the histologic diagnosis? a retrospective analysis was performed based on the comparison of initial and final histologic diagnoses of patients with an odontogenic cystic lesion, that was surgically treated with decompression followed by a definitive surgery.

the study included patients with a histologic diagnosis of an odontogenic cystic lesion, that was surgically treated with decompression followed by a definitive surgery. the study was carried out retrospectively by means of evaluating records, surgical and histologic reports of patients. pre- and post-decompression histologic findings were compared in effort to understand if decompression leads to alteration in histologic character and change in diagnoses of lesions.

Eligibility criteria:
inclusion criteria: * to have an initial diagnosis of an odontogenic cystic jaw lesion confirmed with an incisional biopsy. * the patients must have undergone decompression and, enucleation or enucleation and peripheral ostectomy after decompression period. exclusion criteria: * previously treated patients * the patients with missing information in medical and/or dental records * the patients who did not adhere to follow-up protocol

Keywords: biopsy diagnosis keratocysts odontogenic cysts oral pathology surgical decompression
blood pressure lowering in dialysis (bold) trial

Conditions: Blood Pressure; End Stage Renal Disease on Dialysis (Diagnosis); Chronic Kidney Diseases; Chronic Kidney Disease Stage 5

Summary: blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis. although a systolic blood pressure \<140 mmhg treatment target has been recommended, there remains uncertainty on which blood pressure should be targeted, more specifically that measured in the dialysis unit or at home. observational studies have reported a paradoxical u-shaped associated with dialysis unit (pre-dialysis) systolic blood pressure and cardiovascular events and death (where blood pressure below 140 mmhg is actually linked with poor outcomes). conversely, the same studies have reported a linear association between higher home systolic blood pressure and worse clinical outcomes, where blood pressure below 140 mmhg is associated with better outcomes. this pilot clinical trial aims to address this important question.

blood pressure lowering in dialysis (bold) is a pilot randomized controlled trial of 50 maintenance hemodialysis patients in san francisco and seattle to test whether targeting a home systolic blood pressure \<140 mmhg (versus a pre-dialysis systolic blood pressure \<140 mmhg) is feasible and safe. the study duration is 4 months and blood pressure targets will be achieved through dry weight adjustment and adjustment of standard anti-hypertensive therapies by the study team. the primary outcomes are focused on feasibility and safety. the home blood pressure treatment arm will also have the opportunity to utilize a blood pressure monitor with bluetooth capabilities. the rates of utilization of mobile health technology in this population will also be assessed as an outcome. this pilot trial will provide key data to design a larger trial focused on clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. undergoing in-center, thrice weekly hemodialysis for treatment of end-stage-renal-disease 3. greater than 3 months since initiation of dialysis 4. age 18 years or above 5. able to obtain a brachial blood pressure at dialysis and at home exclusion criteria: 1. pregnancy, anticipated pregnancy, or breastfeeding as this will require increase to more than three time a week dialysis and/or preclude use of some classes of blood pressure medications 2. incarceration or institutionalized living which may prohibit measurement of home blood pressure 3. participation in another intervention study that may affect blood pressure 4. patients in whom systolic blood pressure is not measurable (e.g. those with left ventricular assist devices) 5. hypotension: average pre-dialysis systolic blood pressure \<100 mmhg over last 2 weeks prior to screening while not taking any blood pressure medications 6. life expectancy \<4 months 7. anticipated living donor kidney transplant within 4 months

Keywords: blood pressure hemodialysis end-stage-renal-disease chronic kidney disease
novel virtual reality for burn wound care pain in adolescents

Conditions: Burns

Summary: burn wounds cause intense, complex pain, and subsequent burn wound care causes further intense, episodic pain that is often unrelieved by opioid and non-opioid medications, resulting in under-treatment of pain. further, opioid analgesics can have untoward side effects including respiratory depression, nausea, constipation, pruritus, drowsiness, lethargy, dependence, and induced hyperalgesia. as one of the most severe types of pain, burn wound care pain adds to the trauma pediatric patients already experience from the burn itself impacting quality of life with subsequent behavioral and maladaptive responses, such as agitation, anger, anxiety, hyperactivity, uncooperativeness, aggression, and dissociation. lack of control over the procedure, pain memory, anxiety in anticipation of the repeated painful nature of the procedure, and transmission of clinician distress associated with inflicting procedural pain on the child contribute to the pain perceived. virtual reality (vr) shows great promise as an engaging, interactive, effective non-pharmacologic intervention for various painful healthcare procedures, including burn wound care, therapies, and chronic pain conditions, despite equivocal findings, perhaps due to methodological issues. designs of many studies of vr during burn wound care have been case studies or carefully controlled within-subject designs; sample sizes have been small. recommendations for ongoing research include conducting more rigorous studies including randomized controlled trials (rcts), repeat design studies, testing vr throughout the healthcare procedure, comparing vr to other distraction interventions; and using larger sample sizes. primary aim 1: compare the effectiveness of age-appropriate, consumer available, high technology, interactive vr with standard care (sc) on adolescents' acute procedural pain intensity perception during burn wound care treatment in the ambulatory outpatient clinic setting.


Eligibility criteria:
inclusion criteria: * undergoing burn wound care * first visit to the outpatient arkansas children's hospital (ach) burn clinic or first wound care procedure in the burn clinic without sedation * ages 10 through 21 years (based on a developmental framework of early adolescence: 10-13 years, middle-adolescence: 14-17 years, and late adolescence: 18-21 years) * english speaking (note: not all data collection tools are available in languages other than english) exclusion criteria: * any wounds that may interfere with study procedures (previously, we did not have to exclude facial, head, neck or hand burns but were able to adapt the vr equipment.) * history of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras * incarcerated minors * minors in foster care * presence of a cognitive developmental disability determined on prescreening by presence of a section 504 accommodation plan or title viii individualized educational plan (iep) in school. if iep or 504 plan is unrelated to a cognitive delay, then the adolescent will be included in the study.
the fluoroless-csp trial using electroanatomic mapping

Conditions: Sinus Node Dysfunction; Heart Block AV; LBBB; Heart Failure, Systolic

Summary: the goal of this study is to assess the feasibility, accuracy and safety of performing fluoroless (or low fluoro) conduction system pacing utilizing electro-anatomic mapping (eam) with the carto 3 mapping system (biosense webster inc, irvine, ca) in comparison to a group of patients undergoing conventional conduction system pacing (csp) implants.

the goal of this study is to assess the feasibility, accuracy and safety of performing fluoroless (or low fluoro) conduction system pacing utilizing electro-anatomic mapping (eam) with the carto 3 mapping system (biosense webster inc, irvine, ca) in comparison to a group of patients undergoing conventional conduction system pacing (csp) implants. in this study, we plan to randomize patients to fluoroscopy guided csp vs 3d mapping guided csp implants with low/zero fluoroscopy. the study with assess if 3d eam guided implants can be performed successfully and without any significant increase in device implant related complications.

Eligibility criteria:
inclusion criteria: * age \> 18 years * indication for permanent pacemaker implantation or implantation of cardiac resynchronization therapy device exclusion criteria: * existing cardiac device including pacemaker or cardiac resynchronization therapy device * inability of patient capacity to provide consent for themselves either due to medical or psychiatric comorbidity * pregnancy * difficulty with follow-up
"reduce" - a clinical research study to reduce the incidence of prostate cancer in men who are at increased risk

Conditions: Neoplasms, Prostate

Summary: this 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.


Eligibility criteria:
inclusion criteria: * informed consent to participate in study. * have had a single negative prostate biopsy within 6 months prior to enrollment in study. * have a psa (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a psa between 3.0 and 10 if over age 60. * ability and will to participate in study for 4 years. exclusion criteria: * more than one previous negative prostate biopsy. * history of prostate cancer. * previous prostate surgery. * inability to urinate requiring the need of a catheter during the previous 2 years. * any condition (other than benign prostatic hypertrophy) which may result in urinary symptoms or changes in urine flow rate. * cancer within previous 5 years (other than basal or squamous cell cancers of the skin). * any unstable serious medical condition. * use within the past 12 months of finasteride (proscar or propecia), dutasteride (avodart), testosterone, or drugs that can block the action of male hormones.

Keywords: prostate cancer prevention prostate bph enlarged prostate psa prostate cancer
sulfasalazine in patients with metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.

sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis. sulfasalazine decreased the risk of ulcerative colitis-related colorectal cancer through its anti-inflammatory effect and induction of oxidative stress in cancer cells. furthermore, intact sulfasalazine, but not its metabolites, inhibited the growth and metastasis various cancers.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of stage iv (metastatic) colorectal cancer. staging will be performed according to the american joint committee on cancer (ajcc) 8th edition and will be documented by all investigating parameters of metastatic colorectal cancer 2. male or female patients with age range from 18-65 years old 3. women of childbearing age will be required to be on acceptable forms of contraception 4. performance status \< 2 according to the eastern cooperative oncology group (ecog) score 5. no contraindication to chemotherapy (absence of myelosuppression) 6. adequate liver function (alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< grade 2) according to the national cancer institute-common terminology criteria for adverse events, version 5.0 (nci-ctcae v 5.0) 7. adequate renal function (estimated creatinine clearance (ecrcl), serum creatinine (scr) \< grade 2) according to nci-ctcae, v 5.0 8. adequate hematological parameters (hemoglobin, erythrocytes, platelets, leukocytes and absolute neutrophil count (anc) \< grade 2 according to nci-ctcae, v 5.0 exclusion criteria: 1. pregnant or lactating women 2. patients with concurrent active cancer originating from a primary site other than the colon or rectum 3. patients who have known allergy to sulfasalazine or its metabolites 4. patients with nephrolithiasis, severe vomiting or severe diarrhea 5. patients who are receiving highly plasma protein-bound drugs or drugs with extensive hepatic metabolism such as; coumarin anti-coagulants 6. patients with intestinal or urinary obstruction 7. patients with known glucose-6-phosphate dehydrogenase deficiency or porphyria 8. ongoing treatment with sulfasalazine or mesalamine for ulcerative colitis or rheumatoid arthritis

Keywords: sulfasalazine mcrc
a study of fluzoparib (shr-3162) and temozolomide with or without shr-1316 in treating patients with replapsed small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: this research study is a multicentre phase ⅰb/ⅱ study to evaluate the efficacy and safety of the combination of fluzoparib (shr-3162) and temozolomide with or without shr-1316 in small cell lung cancer


Eligibility criteria:
inclusion criteria: 1. subjects who have recurrent small cell lung cancer confirmed by histology or cytology. 2. failed one prior line of platinum-based chemotherapy. 3. subjects must have measurable disease, at least one lesion, by computed tomography (ct) or magnetic resonance imaging (mri) per recist 1.1 criteria (within 28 days prior to administration of study treatment) ; 4. freshly acquired samples or archived specimens within 12 months before randomization must be provided. 5. eastern cooperative oncology group (ecog) performance status of 0-1. 6. participant must have a life expectancy ≥ 12 weeks. exclusion criteria: 1. active or untreated central nervous system (cns) metastases. 2. uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. 3. history of autoimmune disease. 4. positive test result for human immunodeficiency virus (hiv). 5. active hepatitis b or hepatitis c. 6. severe infections. 7. subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. 8. significant cardiovascular disease. 9. history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
use of micafungin (mycamine®) as antifungal prophylaxis in haematology and onco-haematology

Conditions: Antifungal Prophylaxis; Haemopathy

Summary: the purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in french haematological and onco-haematological units. the efficacy and the safety outcomes will be described.


Eligibility criteria:
inclusion criteria: * adult patient with haemopathy or paediatric patients with haemopathy or solid tumor. * patient hospitalized in haematology, onco-haematology or onco-paediatrics unit. * patient initiating antifungal prophylaxis with micafungin. exclusion criteria: * patient presenting documented fungal infection. * patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.

Keywords: haematology micafungin observational study prophylaxis invasive fungal infection france